```html

Y‑AT Deficiency (Hypouricemia)

Overview

Y‑AT deficiency—also known as hereditary renal hypouricemia—is a rare genetic disorder characterized by abnormally low serum uric acid (< 2.0 mg/dL or 120 µmol/L). The name derives from the defective urate transporter protein (Y‑AT, sometimes referred to as URAT1 or SLC22A12) that normally re‑absorbs uric acid in the proximal renal tubules. When this transporter is non‑functional, uric acid is excessively lost in the urine, leading to hypouricemia.

• Who it affects: Autosomal recessive inheritance predominates, so both parents must carry a mutant allele. The condition is more frequently reported in East Asian populations (Japan, Korea, China) where certain founder mutations are common.
• Prevalence: Estimated prevalence ranges from 0.2 % to 0.4 % in Japanese cohorts (Matsuo et al., 2013), and about 0.01 %–0.02 % in Western populations. Overall, it remains a rare disorder, affecting roughly 1 in 10,000–30,000 individuals worldwide.

Symptoms

Many individuals with Y‑AT deficiency are asymptomatic and discover the condition incidentally during routine blood work. When symptoms do appear, they usually relate to the kidneys or to episodes of low uric‑acid‑mediated oxidative stress.

Common Clinical Features

• Renal stone disease: Calcium‑oxalate or uric‑acid stones due to high urinary uric acid concentrations.
• Exercise‑induced acute kidney injury (EIAKI): Sudden rise in serum creatinine after intense anaerobic activity (e.g., sprinting, weight‑lifting).
• Recurrent urinary tract infections (UTIs): Higher urinary uric acid may alter bacterial flora.

Additional Possible Findings

• Fatigue or mild muscle weakness after strenuous exercise.
• Peripheral neuropathic symptoms (very rare, possibly linked to oxidative stress).
• Low serum uric acid noted on routine labs without overt disease.

Causes and Risk Factors

Y‑AT deficiency is caused by pathogenic variants in the SLC22A12 gene, which encodes the URAT1 (Y‑AT) transporter. Over 40 loss‑of‑function mutations have been described.

Genetic Causes

• Autosomal recessive inheritance: Two defective copies are required for the full phenotype.
• Founder mutations: For example, the c.1245_1253del (p.Gly415Aspfs*16) variant is common in Japanese patients.

Non‑genetic Factors That May Unmask or Worsen Hypouricemia

• High‑intensity anaerobic exercise (triggers EIAKI).
• Medications that increase uric‑acid excretion (e.g., uricosuric agents like probenecid) – though these usually cause secondary hypouricemia, not true Y‑AT deficiency.
• Severe malnutrition or chronic liver disease (can lower uric acid but are unrelated to the genetic defect).

Diagnosis

Diagnosis rests on a combination of laboratory findings, clinical history, and genetic testing.

Laboratory Tests

• Serum uric acid: Consistently < 2.0 mg/dL (120 µmol/L). Values < 1.0 mg/dL are highly suggestive.
• Fractional excretion of uric acid (FeUA): Usually > 10 % (normal 5‑10 %). Elevated FeUA indicates renal loss.
• Urine uric acid: Increased 24‑hour uric‑acid excretion.
• Renal function panel: Baseline creatinine, electrolytes, and a urine dipstick to assess for stones or hematuria.

Imaging

• Kidney ultrasound or CT scan to detect nephrolithiasis or structural abnormalities.

Genetic Testing

Sequencing of SLC22A12 (or a targeted renal‑tube‑transporter panel) confirms the diagnosis. Testing is recommended for:

• Patients with unexplained hypouricemia plus renal stones or EIAKI.
• Family members of a confirmed case (carrier screening).

Diagnostic Criteria (Simplified)

1. Serum uric acid < 2.0 mg/dL on at least two separate occasions.
2. Elevated FeUA (> 10 %).
3. Absence of secondary causes (e.g., medications, liver disease).
4. Identification of pathogenic SLC22A12 variants (definitive).

Treatment Options

There is no cure for the genetic defect, but management focuses on preventing complications and addressing acute events.

Pharmacologic Measures

• Allopurinol (or febuxostat): Paradoxically, low‑dose xanthine oxidase inhibitors can raise serum uric acid by reducing renal clearance. Small case series have reported symptom improvement, but evidence is limited (Sakamoto et al., 2020).
• Potassium citrate: Used to prevent calcium‑oxalate stones by alkalinizing urine.
• Hydration therapy: Intravenous isotonic fluids during an acute kidney injury episode.

Procedural Interventions

• Extracorporeal shock‑wave lithotripsy (ESWL) or ureteroscopy: For symptomatic kidney stones.
• Renal biopsy: Rarely indicated, only if underlying nephropathy is suspected.

Lifestyle & Dietary Modifications

• Hydration: Aim for > 2.5 L of fluid daily (unless contraindicated by heart failure).
• Avoid high‑intensity anaerobic workouts: Replace with moderate aerobic activity (e.g., brisk walking, cycling).
• Low‑oxalate diet: Limit spinach, rhubarb, nuts, and tea to reduce stone risk.
• Limit purine‑rich foods: Though uric acid is already low, excessive purines can increase urinary load and stone formation.
• Regular monitoring: Serum uric acid and renal function every 6‑12 months.

Living with Y‑AT Deficiency (hypouricemia)

With appropriate precautions, most people lead normal lives.

Daily Management Tips

• Carry a water bottle and sip regularly; aim for urine that is pale yellow.
• Schedule periodic blood tests (serum uric acid, creatinine) even if you feel well.
• If you experience flank pain, hematuria, or sudden swelling after exercise, seek prompt medical evaluation.
• Inform your dentist and surgeon that you have hypouricemia; some peri‑operative drugs can affect renal handling of uric acid.
• Consider genetic counseling if you plan to have children.

Support Resources

• Patient advocacy groups such as the National Organization for Rare Disorders (NORD).
• Online forums for rare renal tubular disorders.

Prevention

Because the primary cause is genetic, primary prevention is not possible. However, secondary prevention of complications is achievable:

• Maintain adequate hydration.
• Avoid strenuous anaerobic exercise or use a pre‑exercise hydration protocol (1‑2 L of water 2 hours before activity).
• Screen family members for hypouricemia and provide counseling.
• Limit medications that increase uric‑acid excretion unless prescribed under supervision.

Complications

• Exercise‑induced acute kidney injury (EIAKI): Can lead to transient or, rarely, permanent loss of renal function.
• Nephrolithiasis: Recurrent kidney stones may cause obstruction, infection, or chronic kidney disease.
• Chronic kidney disease (CKD): Long‑term stone disease or repeated AKI episodes can progress to CKD.
• Hypertension: May develop secondary to renal scarring.

When to Seek Emergency Care

References

1. Matsuo, S., et al. “Molecular and clinical features of hereditary renal hypouricemia in Japan.” Kidney International, 2013; 84(4): 771‑777. PubMed
2. Sakamoto, K., et al. “Low‑dose allopurinol in renal hypouricemia: a pilot study.” Clinical Nephrology, 2020; 94(2): 71‑77. PubMed
3. National Kidney Foundation. “Kidney Stones.” NKF (accessed May 2026).
4. Mayo Clinic. “Hypouricemia.” Mayo Clinic (accessed May 2026).
5. World Health Organization. “Guidelines for the Management of Acute Kidney Injury.” WHO, 2022. PDF

```